# CerebrAlcare Pills on CereBral Small VesseL DiseasE（CABLE）

Study · id `cardio:ct-nct05578521` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05578521](<https://clinicaltrials.gov/study/NCT05578521>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05578521

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 114 participants.

## Technical summary

Registry record NCT05578521. Randomized; quadruple masking; primary purpose treatment. Start 2022-06-05 (actual); primary completion 2023-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 114 participants (planned count; ClinicalTrials.gov record NCT05578521, source copy `cardio:ctgov-nct05578521-2022-10-13`, retrieved 2026-11-18)
- Started: 2022-06-05 (actual) (ClinicalTrials.gov record NCT05578521, source copy `cardio:ctgov-nct05578521-2022-10-13`, retrieved 2026-11-18)
- Primary completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT05578521, source copy `cardio:ctgov-nct05578521-2022-10-13`, retrieved 2026-11-18)
- Completion: 2024-03-31 (anticipated) (ClinicalTrials.gov record NCT05578521, source copy `cardio:ctgov-nct05578521-2022-10-13`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT05578521, source copy `cardio:ctgov-nct05578521-2022-10-13`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05578521-2022-10-13`, retrieved 2026-11-18)

## The registry's words

- Brief title: CerebrAlcare Pills on CereBral Small VesseL DiseasE（CABLE）
- Condition: Cerebral Small Vessel Diseases
- Intervention (Drug): Cerebralcare pills
- Intervention (Drug): Cerebralcare pills placebo
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER
- Collaborator: Tasly Pharmaceutical Group Co., Ltd
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cerebral small vessel disease (`cardio:cerebral-small-vessel-disease`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)
- Registry lists this organization as a collaborator: Tasly Pharmaceutical Group Co., Ltd (`cardio:org-tasly-pharmaceutical-group-co-ltd`)

## Provenance

Content hash: 139b280e27176bf06d2c4b75cbd1206845c829f4621ec47227d9537ea1e1a7ed
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
